The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided a positive opinion recommending approval for Sanofi’s Dupixent (dupilumab) as an add-on maintenance therapy to treat children of the age six to 11 years with severe asthma with type 2 inflammation.

The treatment is intended for patients with type 2 inflammation characterised by high blood eosinophils and/or fractional exhaled nitric oxide (FeNO) who are insufficiently controlled on two maintenance treatments. 

A fully human monoclonal antibody, Dupilumab hinders the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathway signalling.

Sanofi is co-developing the antibody with Regeneron as part of a worldwide partnership agreement. 

The company anticipates a final decision from the European Commission (EC) on the application for Dupixent soon.

Presently, Dupixent is approved in the region for use in adults and adolescents aged 12 years and above as an add-on maintenance therapy for severe asthma with type 2 inflammation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The recommendation to expand the indication for usage in children in the EU is based on results from the Phase III clinical trial of Dupixent along with the standard of care.

Findings showed that Dupixent treatment sustainably lowered severe asthma attack rate and quickly boosted lung function within two weeks, with continued improvement up to 52 weeks, in children with uncontrolled moderate-to-severe asthma. 

Safety data from the trial was in line with the already reported safety profile of Dupixent in uncontrolled moderate-to-severe asthma patients of the age 12 years and above.

Injection site reactions, viral upper respiratory tract infections and eosinophilia were the most commonly reported adverse events of Dupixent versus placebo.

So far, dupilumab was analysed in 60 trials that enrolled over 10,000 subjects with several chronic diseases caused partly by type 2 inflammation.

In June 2020, China’s National Medical Products Administration approved Dupixent for the treatment of adults with moderate to severe atopic dermatitis.